Next Article in Journal
Symbiotic and antibiotic interactions between gut commensal microbiota and host immune system
Previous Article in Journal
Self-reported consequences and healthcare costs of falls among elderly women
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

The cost of newly diagnosed breast cancer in Lithuania, 2011

Department of Preventive Medicine, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
Department of Family Medicine, Academy of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania
Author to whom correspondence should be addressed.
Medicina 2015, 51(1), 63-68;
Received: 18 December 2013 / Accepted: 15 November 2014 / Published: 27 January 2015
Background and objective: Although the cost of treating women with breast cancer (BC) is an important component for cost saving and effectiveness in relation to the benefits of BC treatment interventions, there is limited information on the direct cost reported for BC in Lithuania. Therefore the aim of this study was to evaluate annual direct medical cost for newly diagnosed BC in Lithuania in the year 2011.
Materials and methods: The retrospective incidence-based top-down direct cost analysis was used. From January 1 to December 31, 2011 incident cases of BC (N = 1142) registered by the National Health Insurance Fund, the stage determined by Lithuanian Cancer Registry were included in the study.
Results: The total average direct cost of BC amounted per patient was2580 (95% CI 2444–2752) EUR in 2011. The main cost driver per BCpatients was the inpatient hospital stay, respectively 1655 (95% CI 1478–2334) EUR. The average outpatient cost for one BC patient was 564 (95% CI 547–898) EUR. The dominant proportion of inpatient expenditureswas assigned to BC surgery and chemotherapy treatment. The BC direct medical cost increased according to the diagnosed stage of diseases from2409 (95% CI 2196–2621) EUR in stage 1 to3688 (95% CI 2703–4672) EUR in stage 4. The direct medical cost was inversely proportional to age.
Conclusions: The direct BC medical cost estimates provided by this analysis can be used to determine priorities for the future research on BC treatment interventions.
Keywords: Breast cancer; Cost analysis; Direct cost Breast cancer; Cost analysis; Direct cost
MDPI and ACS Style

Ivanauskienė, R.; Domeikienė, A.; Kregždytė, R.; Milašauskienė, Ž.; Padaiga, Ž. The cost of newly diagnosed breast cancer in Lithuania, 2011. Medicina 2015, 51, 63-68.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop